Table V.
Association between GLI1 and SMO expression and clinicopathological characteristics.
| GLI1 | SMO | ||||
|---|---|---|---|---|---|
| Characteristics | Patients, n (%) | IOD (mean ± SD) | P-value | IOD (mean ± SD) | P-value |
| Pathological stagea | |||||
| Well/moderately differentiated | 47 (67.14) | (1.18±0.94)×105 | 0.022b | (1.78±1.05)×105 | 0.322 |
| Poorly differentiated | 19 (27.14) | (1.77±0.90)×105 | (2.10±1.36)×105 | ||
| Invasive extentc | |||||
| Stage 1 | 22 (31.43) | (8.89±6.87)×104 | 0.005d | (2.40±1.51)×105 | 0.019d |
| Stage 2 | 20 (28.57) | (1.33±0.53)×105 | (1.26±0.55)×105 | ||
| Stage 3 | 28 (40.00) | (1.69±1.20)×105 | (1.91±0.92)×105 | ||
| Lymph node statuse | |||||
| N0 | 44 (62.86) | (1.15±0.73)×105 | 0.017b | (1.92±1.26)×105 | 0.853 |
| N1 | 24 (34.29) | (1.72±1.20)×105 | (1.87±0.95)×105 | ||
| Age, years | |||||
| ≤40 | 20 (28.57) | (1.25±0.89)×105 | 0.981f | (1.90±1.33)×105 | 0.747f |
| 41–56 | 41(58.57) | (1.36±1.01)×105 | 0.783g | (1.80±1.11)×105 | 0.567g |
| ≥56 | 9 (12.86) | (1.42±0.84)×105 | 0.788h | (2.17±0.90)×105 | 0.389h |
a
Pathological stage was undetermined in 4 patients.
b
Independent samples t-test.
c
According to the American Joint Committee on Cancer classification.
d
Unequal variance, Kruskal-Wallis test.
e
Lymph node status was undetermined in 2 patients. Equal variance, Fisher's least significant difference test:
f
patients in the ≤40-year-old group compared with patients in the 41–56-year-old group
g
patients in the 41–56-year-old compared with patients in the ≥56-year-old group
h
patients in the ≤40-year-old group compared with patients in the ≥56-year-old group. GLI1, glioma-associated oncogene 1; SMO, smoothened; IOD, integrated optical density; SD, standard deviation.